Gene

CCND1

cyclin D1

Explore in graph →CI-GENE-00040367HGNC:1582 ENSG00000110092 NCBI 595 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (23)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–23 of 23 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CCND1 Amplification8
(prognostic)	Lung Non-Small Cell CarcinomaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	3	accepted

Cohorts

Alteration frequency by cohort (37)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved37 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Mantle Cell Lymphoma (IDIBIPS, PNAS 2013) mcl_idibips_2013	Mantle Cell Lymphoma	Ssm	10	29

Literature

Linked publications (14)

25 per page, newest first.

pubmedPublishedShowing 1–14 of 14 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Cyclin D1 in breast cancer pathogenesis.
· J Clin Oncol · 2005 · PMID 15961768 · validated civic_curation pubmed
Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma.
· Int J Exp Pathol · 2005 · PMID 16309541 · validated civic_curation pubmed
Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics.
· Nat Rev Cancer · 2007 · PMID 17891190 · validated civic_curation pubmed
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B.
· Clin Cancer Res · 2023 · PMID 36853016 · validated civic_curation

CCND1 Amplification + CCND2 Amplification + CCND3 AmplificationCCND1 CCND2 CCND31
Palbociclib	Malignant NeoplasmALIAS	Predictive	B	Does Not Support Sensitivity Response	4	accepted	EID11673 This Phase 2 NCI-MATCH Trial subprotocol Z1B was conducted in 32 patients with either CCND1, 2 or 3 amplification, and were treated with Palbociclib. Squamous cell lung cancer (n=5), adenocarcinoma of… (full text at CIViC) PMID 36853016 · Clark et al., 2023 · Open in CIViC	civic

CCND1 Amplification + CCND2 Amplification + CCND3 AmplificationCCND1 CCND2 CCND31

Palbociclib

Malignant NeoplasmALIAS

Predictive

Does Not Support Sensitivity Response

accepted

EID11673

This Phase 2 NCI-MATCH Trial subprotocol Z1B was conducted in 32 patients with either CCND1, 2 or 3 amplification, and were treated with Palbociclib. Squamous cell lung cancer (n=5), adenocarcinoma of… (full text at CIViC)

PMID 36853016 · Clark et al., 2023 · Open in CIViC

CCND1 Overexpression10
(diagnostic)	Malignant Breast Neoplasm	Diagnostic	B	Supports Positive	4	accepted	EID221 Cyclin D1 overexpression is associated with the ER-positive subtype of breast cancer. PMID 15961768 · Arnold et al., 2005 · Open in CIViC	civic
(prognostic)	Malignant Breast Neoplasm	Prognostic	B	Supports Poor Outcome	4	accepted	EID356 In ER-positive breast cancer patients, Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis. PMID 15961768 · Arnold et al., 2005 · Open in CIViC	civic
〃	Head and Neck Squamous Cell Carcinoma	Prognostic	B	Supports Poor Outcome	4	accepted	EID357 Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in head and neck squamous cell carcinoma. PMID 16309541 · Thomas et al., 2005 · Open in CIViC	civic
〃	Mantle Cell Lymphoma	Prognostic	B	Supports Poor Outcome	4	accepted	EID358 Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in mantle cell lymphoma. PMID 17891190 · Jares et al., 2007 · Open in CIViC	civic
〃	Childhood B-cell Acute Lymphoblastic LeukemiaUNRESOLVED	Prognostic	B	Supports Poor Outcome	2	accepted	EID8115 Reverse phase protein array (RPPA) revealed upregulation of CCND1 at diagnosis in B-ALL relapse patients (n=27) versus patients that did not relapse (n=86, p>.01). 5-year cumulative incidence of relap… (full text at CIViC) PMID 29408328 · Bortolozzi et al., 2018 · Open in CIViC	civic
Bortezomib	Multiple Myeloma	Predictive	C	Supports Sensitivity Response	3	submitted	EID7788 Bone marrow specimens from 20/47 patients treated with bortezomib were analyzed. Researchers analyzed CCND1, CCND2, and CCND3 expression using real-time PCR. Results show all patients with CCND1 ove… (full text at CIViC) PMID 20578819 · Ngo et al., 2010 · Open in CIViC	civic
Palbociclib	Mantle Cell Lymphoma	Predictive	B	Does Not Support Sensitivity Response	2	accepted	EID1536 A pharmacodynamic study (NCT00420056) of 17 mantle cell lymphoma MCL patients was performed using the CDK4/6 inhibitor palbociclib (PD0332991). Patients were verified by IHC, FISH or molecular testing… (full text at CIViC) PMID 22383795 · Leonard et al., 2012 · Open in CIViC	civic
〃	Mantle Cell Lymphoma	Predictive	D	Supports Sensitivity Response	1	accepted	EID1563 In Mantle Cell Lymphoma (MCL), t(11:14)-induced overexpression of cyclin D1 was targeted by CDK4/6 inhibitor Palbociclib (PD0332991). Palbociclib caused Rb dephosphorylation in MCL cell lines and pati… (full text at CIViC) PMID 16690963 · Marzec et al., 2006 · Open in CIViC	civic
Ribociclib	Thyroid Gland Anaplastic CarcinomaALIAS	Predictive	D	Supports Sensitivity Response	3	submitted	EID7790 Study observed the effects of ribociclib (LEE011) on anaplastic thyroid cancer (ATC) and papillary thyroid cancer (PTC) cells. qRT-PCR found Cyclin D1 mRNA to have significantly higher expression in A… (full text at CIViC) PMID 29306020 · Lee et al., 2018 · Open in CIViC	civic
Tamoxifen	Estrogen Receptor-positive Breast CancerUNRESOLVED	Predictive	B	Supports Resistance	3	accepted	EID856 The authors performed a tissue microarray analysis of 167 postmenopausal breast cancers that had been randomized to treatment with or without tamoxifen. ER +ve patients with high CCND1 tumor expressi… (full text at CIViC) PMID 15138475 · Stendahl et al., 2004 · Open in CIViC	civic